The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Autor: Thomas Relander, Elisa Jacobsen Pulczynski, Peter Kamper, Peter de Nully Brown, Michael Roost Clausen, Lars C. Gormsen, Ida Blok Sillesen, Grethe Lauritzsen, Hans Bentzen, Francesco d'Amore, Wolfgang Willenbacher, Michael Thorsgaard, Julie Bondgaard Mortensen, Jette Soenderskov Goerloev, Michael Panny, Erik Segel, Sirpa Leppä

Publikováno v: Aarhus University
University of Helsinki
Clausen, M R, Leppa, S, Brown, P D N, Goerloev, J S, Panny, M, Willenbacher, W, Sillesen, I B, Segel, E, Bentzen, H H N, Thorsgaard, M, Pulczynski, E J, Kamper, P, Gormsen, L C, Mortensen, J, Lauritzsen, G, Relander, T & d'Amore, F 2016, ' The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B-and T-Cell Phenotype-Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial) ', Blood, vol. 128, no. 22, pp. 1782-1782 .

Background: Aggressive non-Hodgkin lymphoma (aNHL) relapsing after high-dose therapy or, in not transplant-eligible patients, after 1st-line chemotherapy represents an unmet clinical need. Therefore, we aimed at evaluating a salvage combination regim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d234ac55d5dd52f061f4b1420dbfd06f
https://doi.org/10.1182/blood.v128.22.1782.1782